Company intelligence / Profile preview
Proto Pharma Ltd
China
- Ownership
- Private
- Development stage
- Other
01
Overview
Proto Pharma Ltd has developed and commercialized artemether, an antimalarial drug targeting the ATP2A1 x SERCA2 protein. Artemether is approved in China and has been evaluated in at least one completed Phase 3 trial comparing its ArTiMist™ formulation to intravenous quinine for severe or complicated falciparum malaria in children. The company appears to focus on translational medicine and collaborates with academic institutions such as Fudan University and the Shanghai Institute of Materia Medica.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Proto Pharma Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proto Pharma Ltd.